Prana loss rises to $10m, as R&D spend increases
Thursday, 26 August, 2004
Melbourne brain-disease drug-discovery company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) has reported an after-tax loss of $9.9 million in the year to June.
The loss, up 116 per cent on last year’s result, came despite a 28 per cent lift in revenue, to $2,3 million which included a $1.35 million AusIndustry Start Grant to support the development of the PBT2, Prana’s second-generation lead compound for Alzheimer’s Disease
The biggest contributors to the increased loss were a sharp rise in R&D expenditure, from $1.7 million to $5.3 million and a rise in personnel costs from $1.3 million to $2.7 million.
Prana’s total current assets are valued at $29.7 million up from $3.5 million in 2003. Total non-current assets, including intangibles, were $11.5 million down on last year’s $12.6 million.
The company raised $34.6 million from two share issues, in September 2003, and June this year, resulting in a net increase in cash holdings of $26.3 million.
Giving rotavirus vaccine at birth benefits gut bacteria
Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...